Beneficial side-effects of colchicine for patients with gout
In The Lancet Rheumatology, Edoardo Cipolletta and colleagues present an observational study comparing the risk of cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis.1 Notably, the authors show that the risk of cardiovascular events was reduced in those prescribed colchicine (0·5–1·0 mg per day) for a mean duration of 50 days, highlighting a potential beneficial effect of this flare prophylaxis.
